Post on 28-Oct-2014
transcript
New Therapies for Diabetes
Abe DeSantis, MDClinical Asst. Professor
Division of Metabolism, Endocrinology and Nutrition
University of Washington Medical Center
Prevalence of Diabetes in United States
16.1 19.3
23.6
0
5
10
15
20
25
1988-94 1999-2002 2008
20%
http://www.cdc.gov/media/pressrel/2008/r080624.htm
Mil
lion
22%
Therapeutic Options forType 2 DM
• 1995• Sulfonylurea• INSULIN
– NPH– Regular– Ultralente
• 2008• Sulfonylurea• INSULIN
– NPH– Regular– Insulin analogues– Inhaled
• Metformin• TZDs• Alpha glucosidase inhibitors• Meglitinides• Endocannabinoid receptor -• Incretin mimetics• Amylin analogues• DPP IV inhibitors
Therapeutic Options forType 2 DM
• 1995• Sulfonylurea• INSULIN
– NPH– Regular– Ultralente
• 2008• Sulfonylurea• INSULIN
– NPH– Regular– Insulin analogues– Inhaled
• Metformin• TZDs• Alpha glucosidase inhibitors• Meglitinides• Endocannabinoid receptor-• Incretin mimetics• Amylin analogues• DPP IV Inhibitors
Sites of Action by Therapeutic Options Presently Available to Treat Type 2 Diabetes
GLUCOSE ABSORPTION
GLUCOSE PRODUCTIONBiguanidesBiguanides
(Thiazolidinediones)
MUSCLEMUSCLE
PERIPHERAL GLUCOSE UPTAKE
Thiazolidenediones(Biguanides)(Biguanides)
PANCREAS
INSULIN Secretion/replacementSulfonylureasSulfonylureasMeglitinidesMeglitinidesExenatideExenatide
DPP4 InhibitorsDPP4 InhibitorsInsulinInsulin
ADIPOSE ADIPOSE TISSUETISSUE
LIVERLIVER
alpha-glucosidase inhibitors
INTESTINE
Adapted from Sonnenberg and Kotchen. Curr Opin Nephrol Hypertens 1998;7(5):551–5
STOMACHDELAYED EMPTYING Exenatide, Pramlintide
BRAINEndocannabinoidReceptor BlockersExenatidePramlinitide
0 3 6 9 12
0
100000
200000
300000
400000
Time After Meal (h)
Pla
sma
Exe
nd
in-4
Co
nce
ntr
atio
n (
pg
/mL
)
Exendin-4 in the Gila Monster
♦Exendin-4 was originallyisolated from thesalivary secretions ofthe Gila monster
♦Exendin-4 wassubsequently found tocirculate as a meal-related peptide in this animal
Data from Young AA. Insulin Resistance and Insulin Resistance Syndrome 2002, 235-262
Reduced Incretin Effect in Type 2 Diabetic Patients
00
2020
4040
6060
8080
INS
UL
IN (
INS
UL
IN (
mU
/Lm
U/L ))
00 3030 6060 9090 120120 150150 180180TIME (min)TIME (min)
Control SubjectsControl Subjects
Intravenous GlucoseIntravenous Glucose
Oral GlucoseOral Glucose
**** **
**** ** **
00
2020
4040
6060
8080
INS
UL
IN (
INS
UL
IN (
mU
/Lm
U/L ))
00 3030 6060 9090 120120 150150 180180TIME (min)TIME (min)
Type 2 Diabetic PatientsType 2 Diabetic Patients
****
**
Nauck M, et al. Diabetologia. 1986;29:46-52.
Incretin effect
GLP-1 Modes of Action in Man
GLP-1 Modes of Action in Man
GLP-1 is secretedfrom the L-cells
in the jejunumand ileum
GLP-1 is secretedfrom the L-cells
in the jejunumand ileum
• Stimulates insulin secretion• Stimulates insulin secretion
• Suppresses glucagon secretion• Suppresses glucagon secretion
• Slows gastric emptying• Slows gastric emptying
Long term effectsdemonstrated in animals…Long term effectsdemonstrated in animals…• Increases beta-cell cell mass and maintains beta-cell efficiency• Increases beta-cell cell mass and maintains beta-cell efficiency
• Reduces food intake• Reduces food intake
Upon ingestion of food…Upon ingestion of food…
Drucker DJ. Curr Pharm Des 2001; 7:1399-1412Drucker DJ. Mol Endocrinol 2003; 17:161-171
Drucker DJ. Curr Pharm Des 2001; 7:1399-1412Drucker DJ. Mol Endocrinol 2003; 17:161-171
Adapted from Deacon CF, et al. Diabetes. 1995;44:1126-1131.
GLP-1 Secretion and Inactivation
IntestinalGLP-1
release
GLP-1 (7-36)active
Mixed meal
GLP-1 (9-36)inactive
(>80% of pool)
DPP-4
T1/2 = 1 to 2 min
Exenatide (Byetta)
♦ Synthetic exendin-4♦ In clinical studies, exenatide exhibited actions
that are similar to those of GLP-1:♦ Stimulation of insulin secretion only when
blood glucose concentrations are elevated♦ Suppression of postprandial glucagon
secretion♦ Slowing of gastric emptying
Acute Meal Challenge Study:Postprandial
Glucose and Glucagon Concentrations
Pla
sma
Glu
cag
on
(p
g/m
L)
Pla
sma
Glu
cose
(m
mo
l/L
)
0
5
10
15
20Exenatide or Placebo
Standardized Breakfast
0 60 120 180 240 300
Time (min)
0 120 18030 9060 150
Time (min)
50
100
150
200
250Exenatide or Placebo
Standardized Breakfast
PlaceboExenatide 0.1 µg/kg
PlaceboExenatide 0.1 µg/kg
Data from Kolterman OG, et al. J Clin Endocrinol Metab 2003; 88:3082-3089
n=20Mean ± SE
Proportion of Subjects Achieving A1C 7% at Week 30
Evaluable Population with Baseline A1C >7%Placebo
5 µg exenatide10 µg exenatide
DeFronzo R, et al. ADA 64th Annual Scientific Sessions, June 2004
Evaluable with baseline A1C >7%, N = 234 (Placebo, n =77; 5 µg exenatide, n =79; 10 µg exenatide, n = 84)*P <0.01, **P <0.0001
0
10
20
30
40
50
13%
32%
46%
*
**
Per
cen
t o
f S
ub
jec
ts
Ach
ievi
ng
A1C
≤7%
Date on file, Amylin Pharmaceuticals, Inc.
% Incidence of Nausea
0-4 >12-16 >16-20 >20-24 >24-28 >28 >4-8
>8-12
Placebo (N = 483)Exenatide 5 mcg BID (N = 480)Exenatide 10 mcg BID (N = 483)
Large Phase 3 Clinical Studies – Combined (ITT)
Large Phase 3 Clinical Studies – Combined (ITT)
Dose increased from 5 mcg to 10 mcg at wk 4
100
0
15
30
45
60
75
Time (wk)
Open-Label Study: Body Weight Over 24 Weeks
-4.0
-3.0
-2.0
-1.0
0.0
0 4 8 12 16 20 24
Evaluable population (N=105)
Mean (SE) Body Weight
(kg)
1.0
Time (wk)
Baseline = 89 ± 2 kg
-3.4 kg
Data from Poon T, et al. Diabetic Med 2004; 21(suppl 2):A45
Exenatide (Byetta)
♦ Pen prefill- one month’s supply♦ Given bid, 30-60 minutes prior to meal (250 cal)♦ Nausea experienced by almost all initially, typically
remits within days♦ Start at 5 mcg BID, then increase to 10 mcg BID after 1
month♦ Current indication: failing SFU, metformin, or both♦ Not FDA approved with insulin or monotherapy♦ Pancreatitis warning
Typical Results?
♦ Not magic wand for everyone-
15% no effect
evidence for loss of treatment response♦ Fullness sensation- Gastric or CNS?♦ Relearning to eat- satiety sense♦ Data support 20% fewer calories ingested♦ Expense and insurance coverage
TrendsTrends
• A1c and weight loss do not correlate• Prandial insulin dose decreases dramatically• Minimal basal insulin dose change• For women, weight loss persists in physically
active, in men not associated• Liraglutide- daily administration Phase 3 Trials
Adapted from Deacon CF, et al. Diabetes. 1995;44:1126-1131.
GLP-1 Secretion and Inactivation
IntestinalGLP-1
release
GLP-1 (7-36)active
Mixed meal
GLP-1 (9-36)inactive
(>80% of pool)
DPP-4
T1/2= 1 to 2 min
Inhibition of DPP-4 Increases Active GLP-1
GLP-1 (9-36)inactive
IntestinalGLP-1
release
Mixed meal
GLP-1 (7-36)active
DPP-4
Adapted from Rothenberg P, et al. Diabetes. 2000;49(suppl 1):A39.
DPP-4inhibitor
GLP-1 (7-36)active
DPP 4 Inhibitors
♦ Once daily ingestion♦ Reduce fasting and postprandial glucose,
reduce HbA1c♦ Decrease glucagon response to ingested
meal♦ Initial studies in combination with metformin♦ 2 drugs
Vildagliptin Galvus® ( Novartis)
Sidagliptin Januvia ™ (Merck)
Effects of DPP-4 Inhibition
• ß-cell function
• Glucagon secretion
• Insulin sensitivity
• ß-cell mass
Adapted from Ahrén B, et al. J Clin Endocrinol Metab. 2004;89:2078–2084.
Glycemic, Incretin, and Islet Cell Response to a Meal After 4 Weeks of Treatment With Vildagliptin
GlucagonGlucose
0
25
50
75
–30 0 30 60 90 120 150 180 210 240
Time (min)
0
5
10
15
20
25
–30 0 30 60 90 120
Time (min)
5.0
8.0
11.0
14.0
50
75
100
125
GL
P-1
[7-
36a
mid
e]
(pm
ol/
L)
Glu
cag
on
(n
g/L
)Active GLP-1Insulin
Glu
cose
(m
mo
l/L
)IR
I (µ
U/m
L)
PlaceboVildagliptin (100 mg qd)
GLP-1 = glucagon-like peptide–1
Vildagliptin and -Cell Preservation and Regeneration (neonatal rat model)
Vehicle Vildagliptin
Brd
U-p
os
itiv
e c
ell
s (
%)
Ap
ota
g-p
os
itiv
e c
ell
s (
%)
Vehicle Vildagliptin Vehicle Vildagliptin
P<.001
P<.05
P<.05
-c
ell
ma
ss
(m
g)
Replication ß-cell mass
Vildagliptin
60 mg/kg, po x 21 days
Day 7 Day 21
Vehicle Vildagliptin
• Insulin
Adapted from Duttaroy A, et al. Diabetes 2005. 54 (suppl 1): A141.Abstract 572-P.
Apoptosis
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.0
0.5
1.0
1.5
2.0
2.5
0
20
40
60
80
100
120
6.8
7.2
7.6
8.0
8.4
–4 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Weeks
Vildagliptin/Metformin (extension, n = 42)Placebo/Metformin (extension, n = 29)
Placebo/Metformin (initial study, n = 51)
HbA
1c
(%)
Vildagliptin/Metformin (initial study, n = 56)
Ahrén et al, Diabetes Care 27:2874-2880 (2004)
Combination of Vildagliptin and Metformin
P < .0001
–1.1 ± 0.2%
Summary of DPP-4 Inhibition
• Increases fasting and postprandial GLP-1 levels• Reduces fasting and postprandial glycemia• Improves ß-cell function
– Increases insulin secretion, reduces proinsulin/insulin ratio– Increases beta-cell mass
• Inhibits glucagon secretion– Reduces hepatic glucose production
• Increases insulin sensitivity• Reduces postprandial lipemia• No effect on gastric emptying or body weight• Reduces HbA1c by ~1%• Is safe and tolerable in short term• In renal impairment, dose decreased by 50%
Amylin
• Discovered in 1987• Co-secreted with insulin
– Absent in type 1 DM, deficient in type 2 DM
• Slows gastric emptying and digestion
• Decreases post-prandial glucagon
• Satiety effect CNS
Amylin Is Deficient in Diabetes
Without diabetes (n = 27)Late-stage type 2 (n = 12)Type 1 (n = 190)
Data from Kruger D, et al. Diabetes Educ 1999; 25:389-398
Time After Sustacal® Meal (min)
0
5
10
15
20
-30 0 30 60 90 120 150 180
Meal
Late Stage Type 2
Type 1
Without Diabetes
Pla
sma
Am
ylin
(p
M)
Pramlintide Improves Postprandial GlucoseTYPE 1 DIABETES
100
150
200
250
300
0 60 120 180 240
Time Relative to Meal and Pramlintide (min)
Mean (SE) Plasma Glucose
(mg/dL)
100
150
200
250
300
0 60 120 180 240
Mean (SE) Plasma Glucose
(mg/dL)
Lispro InsulinPramlintide 60 g + Lispro Insulin
Regular InsulinPramlintide 60 g + Regular Insulin
Pramlintide + Lispro insulin (n = 20)Pramlintide + Regular insulin (n = 18) Weyer C, et al. Diabetes Care 2003; 26:3074-3079
Pramlintide Improves Postprandial Glucose
TYPE 2 DIABETES
100
120
140
160
180
200
220
240
260
0 60 120 180 240
Time Relative to Meal and Pramlintide (min)
Pla
sma
Glu
cose
(m
g/d
L)
0
50
100
150
200
Time Relative to Meal and Pramlintide (min)
Pla
sma
Pra
mli
nti
de*
(p
mo
l/L
)
Placebo + Lispro InsulinPramlintide 120 g + Lispro Insulin
Pramlintide 120 g + Lispro Insulin
0 60 120 180 240
Data from Maggs DG, et al. Diabetes Metab Res Rev 2004; 20:55-60Pramlintide Acetate Prescribing Information, 2005Data on file, Amylin Pharmaceutical, Inc.
Pramlintide Clinical EffectsTYPE 2 DIABETES COMBINED PIVOTALS
-2
-1
0
1
***
**
**
**
**
****-4
-2
0
2
4
6
8
-0.8
-0.6
-0.4
-0.2
0
Insulin Use (%) A1C (%) Weight (kg)
Week 4 Week 13Week 26Week 4 Week 13Week 26Week 4 Week 13 Week 26
Placebo + Insulin 120 g Pramlintide BID + Insulin
Placebo + insulin (n = 284), Baseline A1C = 9.3%Pramlintide + insulin (n = 292), Baseline A1C = 9.1%*P <0.01, **P <0.0001; ITT population; Mean (SE) change from baseline
Pramlintide specifics:
♦ Injectable- insulin syringe♦ Starting dose Type 1 DM 15 mcg (2.5 units)♦ Starting dose Type 2 DM 60 mcg (10 units)♦ Titrate as tolerated every 3 days
♦ Symlin® pens (60 and 120 mcg)♦ Use at the time of a meal (250 cal)♦ Separate injection from insulin♦ Decrease dose of prandial insulin by 50%♦ Potentially less nausea than with exenatide
Severe Hypoglycemia
0-3 months 3-6 months
Type 1 Diabetes 5.7% (N=265) 3.8% (n=213)
Type 2 Diabetes 0.6% (N=265) 0.7% (n=213)
“Open-label, clinical practice study”
Symlin Package Insert
Case #1• Mrs LH, 82 yo F with known valvular
Heart disease, CAD, HTN, T2DM for 22 yrs
• Cardiac Meds
• 70/30 Humulin insulin – 23 u AM and 18u PM– A1c = 6.4%
• Issues with hypoglycemia lately
Meter DownloadCase #1
TIME 1-6AM 6AM-9AM 9AM-11A 11AM-2PM 2-4PM 4-8PM 8-10P 10-1AM ALL # 4 30 4 23 5 28 8 30 132AVG 84 154 186 138 88 113 98 192 131.625SD 72 86 104 98 100 64 82 96 87.75RANGE 55-103 82-286 44-388 92-204 54-102 54-212 38-242 114-335 38-388
Meter DownloadCase #1
TIME 1-6AM 6AM-9AM 9AM-11A 11AM-2PM 2-4PM 4-8PM 8-10P 10-1AM ALL # 4 30 4 23 5 28 8 30 132AVG 84 154 186 138 88 113 98 192 131.625SD 72 86 104 98 100 64 82 96 87.75RANGE 55-103 82-286 44-388 92-204 54-102 54-212 38-242 114-335 38-388
Meter Download Case #1
TIME 1-6AM 6AM-9AM 9AM-11A 11AM-2PM 2-4PM 4-8PM 8-10P 10-1AM ALL # 4 30 4 23 5 28 8 30 132AVG 84 154 186 138 88 113 98 192 131.625SD 72 86 104 98 100 64 82 96 87.75RANGE 55-103 82-286 44-388 92-204 54-102 54-212 38-242 114-335 38-388
Meter Download Case #1
TIME 1-6AM 6AM-9AM 9AM-11A 11AM-2PM 2-4PM 4-8PM 8-10P 10-1AM ALL # 4 30 4 23 5 28 8 30 132AVG 84 154 186 138 88 113 98 192 131.625SD 72 86 104 98 100 64 82 96 87.75RANGE 55-103 82-286 44-388 92-204 54-102 54-212 38-242 114-335 38-388
Regular Insulin
NPH Insulin
Meter Download Case #1
TIME 1-6AM 6AM-9AM 9AM-11A 11AM-2PM 2-4PM 4-8PM 8-10P 10-1AM ALL # 4 30 4 23 5 28 8 30 132AVG 84 154 186 138 88 113 98 192 131.625SD 72 86 104 98 100 64 82 96 87.75RANGE 55-103 82-286 44-388 92-204 54-102 54-212 38-242 114-335 38-388
Regular Insulin
NPH Insulin
Meter Download Case #1
TIME 1-6AM 6AM-9AM 9AM-11A 11AM-2PM 2-4PM 4-8PM 8-10P 10-1AM ALL # 4 30 4 23 5 28 8 30 132AVG 84 154 186 138 88 113 98 192 131.625SD 72 86 104 98 100 64 82 96 87.75RANGE 55-103 82-286 44-388 92-204 54-102 54-212 38-242 114-335 38-388
Rapid Insulin analogue
Glargine Insulin
Case #1• Decision to convert to basal bolus
therapy• TDD = 70/30 23uAM and 18uPM= 41• Due to hypoglycemia TDD = 36 units• 50% basal 18 units glargine• Breakfast 5u Lunch 4u Dinner 8u• Correction 1500/36 = 42
– ISF 1:40 day– ISF 1:80 night
target 80correction factor 1 units for every mg/dl over target
Premeal Novolog Humalog X Apidra Regularblood glucose < 80 80 to 150 to 190 to 230 to 270 to 310 to 350 to 391 to 431 to 471 to 511 to 551 to 591 to 631 to
(mg/dl) 149 189 229 269 309 349 390 430 470 510 550 590 630 670
Breakfast 5
Lunch 4
Dinner 8BED
Long Acting Insulin _Lantus _Detemir _ NPH _ 70/30 _ 75/25X
AM __18____units at bedtime
150
19 20 21
17 18
16 17
11 12 13 14 15 16 17 18
12 13 14 158 9 10 116
10
754
8
Dose if no BG check
40
54
7
3
9
13 14 15 1611 12106 7 8 9
12:00 AM 6:00 AM 12:00 6:00 PM 12:00 AM
Glu
co
se
(m
g/d
L)
400
300
200
100
0
Glucose measurement
Insulinbolus
TargetRange
Fingerstick Blood Glucoses
12:00 AM 6:00 AM 12:00 6:00 PM 12:00 AM
Glu
co
se
(m
g/d
L)
400
300
200
100
0
Glucose measurement
Insulinbolus
TargetRange
Continuous Glucose Monitoring Provides More Comprehensive Picture of Glycemic Patterns
Glucose Sensors
GuardControl StudyGuardControl Study162 subjects (half children/half adults) T1 DM randomized to: Guardian RT continuously Guardian RT 3 days every 2 weeks Continued SBGMInitial A1c >8.1%
P-value: Change from baseline between Continuous & Control groups
Control
Intermittent useContinuous use
Deiss D, et al. Diabetes Care. 2006;12:2730-2732.
MealCalibration
140 mg/dL
170 mg/dL
calibrate during steady-state conditions
Capillary blood
Interstitial fluid
Sensor “Lag”There is typically a 7 to 15 min lag between ISF glucose and blood glucose
Why the Sensor Lag Is So Important To Understand
• Calibration
• Upward trend: more insulin is needed
• Downward trend: beware of hypoglycemia!
• Because of these issues, rt-CGM does not replace SMBG yet!
Combined glucose sensing and insulin delivery
1 month CGM: ave 141/ SD64
6 months CGM: 123/49
Future Options• Inhaled insulin
– Tritiated compound Mannkind Afresa ® clinical trials
• DPP 4 inhibitors– Sitagliptin,
vildagliptin,saxagliptin,linagliptin,alogliptin
• Extended GLP-1 agonists– Exenatide LAR (once weekly)– Liraglutide once daily
• Newer CGMS
Thank You !